Maincent P - Search Results

1

PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.

Parent M, Nouvel C, Koerber M, Sapin A, Maincent P, Boudier A. Parent M, et al. Among authors: maincent p. J Control Release. 2013 Nov 28;172(1):292-304. doi: 10.1016/j.jconrel.2013.08.024. Epub 2013 Sep 1. J Control Release. 2013. PMID: 24001947 Review.

2

Are in situ formulations the keys for the therapeutic future of S-nitrosothiols?

Parent M, Boudier A, Dupuis F, Nouvel C, Sapin A, Lartaud I, Six JL, Leroy P, Maincent P. Parent M, et al. Among authors: maincent p. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):640-9. doi: 10.1016/j.ejpb.2013.08.005. Epub 2013 Aug 13. Eur J Pharm Biopharm. 2013. PMID: 23954508

3

One-week in vivo sustained release of a peptide formulated into in situ forming implants.

Parent M, Clarot I, Gibot S, Derive M, Maincent P, Leroy P, Boudier A. Parent M, et al. Among authors: maincent p. Int J Pharm. 2017 Apr 15;521(1-2):357-360. doi: 10.1016/j.ijpharm.2017.02.046. Epub 2017 Feb 20. Int J Pharm. 2017. PMID: 28232200

4

Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization.

Camargo JA, Sapin A, Nouvel C, Daloz D, Leonard M, Bonneaux F, Six JL, Maincent P. Camargo JA, et al. Among authors: maincent p. Drug Dev Ind Pharm. 2013 Jan;39(1):146-55. doi: 10.3109/03639045.2012.660952. Epub 2012 Mar 8. Drug Dev Ind Pharm. 2013. PMID: 22397675

5

Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles.

Javot L, Sapin A, Scala-Bertola J, Vigneron C, Lecompte T, Maincent P. Javot L, et al. Among authors: maincent p. Thromb Haemost. 2010 Jun;103(6):1254-67. doi: 10.1160/TH09-10-0684. Epub 2010 Apr 13. Thromb Haemost. 2010. PMID: 20390227

6

Composite microparticles with in vivo reduction of the burst release effect.

Sheikh Hassan A, Sapin A, Lamprecht A, Emond E, El Ghazouani F, Maincent P. Sheikh Hassan A, et al. Among authors: maincent p. Eur J Pharm Biopharm. 2009 Nov;73(3):337-44. doi: 10.1016/j.ejpb.2009.07.009. Epub 2009 Aug 3. Eur J Pharm Biopharm. 2009. PMID: 19651210

7

Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables.

Camargo JA, Sapin A, Daloz D, Maincent P. Camargo JA, et al. Among authors: maincent p. J Microencapsul. 2010;27(7):609-17. doi: 10.3109/02652048.2010.501397. J Microencapsul. 2010. PMID: 20695833

8

In Situ Microparticles Loaded with S-Nitrosoglutathione Protect from Stroke.

Parent M, Boudier A, Perrin J, Vigneron C, Maincent P, Violle N, Bisson JF, Lartaud I, Dupuis F. Parent M, et al. Among authors: maincent p. PLoS One. 2015 Dec 8;10(12):e0144659. doi: 10.1371/journal.pone.0144659. eCollection 2015. PLoS One. 2015. PMID: 26646285 Free PMC article.

9

Understanding the Thermodynamic Mechanisms Leading to the Binding of Albumin to Lipid Nanocapsules.

Umerska A, Sapin-Minet A, Parent M, Tajber L, Maincent P, Boudier A. Umerska A, et al. Among authors: maincent p. Langmuir. 2020 Apr 21;36(15):4165-4173. doi: 10.1021/acs.langmuir.9b03147. Epub 2020 Apr 7. Langmuir. 2020. PMID: 32223171

10

[Which future in cardiovascular therapy for nitric oxide and its derivatives?].

Parent M, Dupuis F, Maincent P, Vigneron C, Leroy P, Boudier A. Parent M, et al. Among authors: maincent p. Ann Pharm Fr. 2013 Mar;71(2):84-94. doi: 10.1016/j.pharma.2012.12.004. Epub 2013 Jan 23. Ann Pharm Fr. 2013. PMID: 23537409 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters